Abstract
Presented here is a case of Aspergillus osteomyelitis in an immunocompetent patient that progressed despite surgery and prolonged treatment with liposomal amphotericin B; the report is followed by a review of the literature. The review of this case and 41 similar cases found an overall cure rate of 69%. The importance of surgery when amphotericin B is used as first-line therapy is indicated by a 14% cure rate when amphotericin B is used alone compared to 75% when combined with surgery. When therapy is failing or surgery is contraindicated, dose escalation using a lipid formulation was not effective. On review, the addition of another agent, in particular 5-fluorocytosine, appears to be more beneficial. The patient reported here responded rapidly to voriconazole, a promising new antifungal agent for Aspergillus infections.
MeSH terms
-
Amphotericin B / administration & dosage*
-
Antifungal Agents / administration & dosage
-
Aspergillosis / diagnosis
-
Aspergillosis / drug therapy*
-
Aspergillosis / immunology
-
Aspergillus / drug effects*
-
Aspergillus / isolation & purification
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Resistance, Fungal
-
Follow-Up Studies
-
Humans
-
Immunocompetence
-
Lumbar Vertebrae / pathology
-
Magnetic Resonance Imaging / methods
-
Male
-
Middle Aged
-
Osteomyelitis / diagnosis
-
Osteomyelitis / drug therapy
-
Osteomyelitis / immunology
-
Pyrimidines / administration & dosage*
-
Risk Assessment
-
Severity of Illness Index
-
Spondylitis / diagnosis
-
Spondylitis / drug therapy*
-
Spondylitis / immunology
-
Treatment Failure
-
Treatment Outcome
-
Triazoles / administration & dosage*
-
Voriconazole
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
Amphotericin B
-
Voriconazole